NeogenTC

Based in Seoul, South Korea and founded in 2020, NeogenTC Corp. is a company specializing in immune cell therapy such as tumor-infiltrating lymphocyte cell therapy and T-cell receptor (TCR) modified T-cell (TCR-T) therapy with its own platform technology. The TCR-T cell therapy developed by Neogen TC is a T-cell receptor-transformed T-cell, which is a gene cell therapy product that incorporates various state-of-the-art technologies such as discovery of new antigens, T-cell receptor (TCR) sequence analysis, and gene transfer technology. The company's research and development on T-cell enginering began in 2017, followed by a Neoantigen-specific T-cell research which was selected by the Oncology Immunity Research Group from Asan Medical Center in 2018. In 2019, its research in Tumor-infiltrating lymphocyte (TIL) cell therapy development was selected by Ministry of Health and Welfare as a health care technology project. NeogenTC Corp. NeogenTC Corp. is developing immune cell therapy such as tumor-infiltrating lymphocyte cell therapy and T-cell receptor (TCR) modified T-cell (TCR-T) therapy with its own platform technology based on tumor immunology. The company plans to expand and relocate its headquarters and research institute to Hanam-si, Gyeonggi-do in the second half of 2021, recruit human resources for R&D, expand infrastructure for research facilities and to build its own TCR-T platform technology as a TCR-T cell therapy that can target solid cancers that are difficult to treat.

1. Series A

   Apr 6, 2021

   Amount

   $13M

   Investors

   Locked

2. Seed

   Jun 1, 2020

   Amount

   Undisclosed

   Investors

   Locked